Genenta Science and Anemecyte伙伴,促进生产用于基因疗法的扁皮拉质DNA。 Genenta Science and Anemocyte partner to enhance production of lentiviral plasmid DNA for gene therapies.

基因科学和Anemocyte已经建立了战略合作伙伴关系,以改善现成的晶体病毒载体等离子体DNA的生产,这是基因和细胞疗法的关键组成部分. Genenta Science and Anemocyte have formed a strategic partnership to improve the production of off-the-shelf lentiviral vector plasmid DNA, a key component in gene and cell therapies. 合作的目的是提高制造业的效率、可扩展性和一致性,有可能降低成本,加快治疗发展。 The collaboration aims to boost manufacturing efficiency, scalability, and consistency, potentially reducing costs and speeding up therapy development. 虽然没有披露具体产品或时间表,但这项努力解决了基因治疗供应链中的关键瓶颈问题。 While specific products or timelines were not disclosed, the effort addresses critical bottlenecks in gene therapy supply chains. 这种合作关系建立在Genenta的临床验证技术和Anemocyte在核酸制造方面的专业知识之上. The partnership builds on Genenta’s clinically validated technology and Anemocyte’s expertise in nucleic acid manufacturing.